Table 3.

The key outcomes of the ENGAGE-AF TIMI 48 trial,¹⁶ comparing edoxaban 30 and 60 mg to warfarin treatment

Complications	Low-dose edoxaban (30 mg)	High-dose edoxaban (60 mg)	Warfarin (therapeutic)	Outcome
Stroke and embolism prevention	1.61% (P=0.005)	1.18% (P=0.001)	1.50%	Reduced by up to 0.32%
Bleeding rates	1.61% (P=0.001)	2.75% (P=0.001)	3.43%	Reduced by up to 1.82%
Intracranial hemorrhage	0.26% (P=0.001)	0.39% (P=0.001)	0.85%	Reduced by up to 0.59%
Cardiovascular death	2.71% (P=0.008)	2.74% (P=0.013)	3.17%	Reduced by up to 0.46%